Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BuzzFeed Q3 2026 net loss more than doubles year on year to $18.66 million

BuzzFeed Q3 2026 net loss more than doubles year on year to $18.66 million

BitgetBitget2026/11/04 23:55
  • BuzzFeed's Q3 2026 net loss more than doubled year-over-year to $18.66 million, while revenue fell 44% to $26.03 million.
  • Commerce and other revenue dropped 71% year-over-year to $4.84 million, while advertising revenue declined 31% to $15.39 million.
  • July's restructuring reduced the workforce and dedicated contractors by approximately 35%, with expected annualized savings of approximately $30 million.
  • Management deferred its full-year 2026 financial outlook while integrating changes from the Allen Family Digital transaction and July restructuring.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BuzzFeed Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103446398) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss